AW
ACAD icon

Ankerstar Wealth’s Acadia Pharmaceuticals ACAD Stock Holding History

Ankerstar Wealth’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$278 Sell
11
-15
-58% -$330 ﹤0.01% 821
2026
Q1 		$579 Buy
26
+10
+63% +$239 ﹤0.01% 577
2025
Q4 		$427 Buy
+16
New +$382 ﹤0.01% 699

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Ankerstar Wealth's ACAD Position: Q2 2026 in Review

Ankerstar Wealth reduced its Acadia Pharmaceuticals (ACAD) stake by 58% in Q2 2026, selling an estimated $330 and leaving 11 shares worth $278. The position accounts for ﹤0.01% of the portfolio, ranked #821.

Ankerstar Wealth first reported a position in ACAD in Q4 2025 and has held it in 3 quarters since. The position peaked at $579 in Q1 2026. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Ankerstar Wealth held 11 shares of Acadia Pharmaceuticals worth $278 as of Q2 2026.
  • Ankerstar Wealth sold 15 Acadia Pharmaceuticals shares in Q2 2026, an estimated $330.
  • Acadia Pharmaceuticals made up ﹤0.01% of Ankerstar Wealth's portfolio in Q2 2026, its #821 holding.
  • Ankerstar Wealth first reported a position in Acadia Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Ankerstar Wealth's Acadia Pharmaceuticals position peaked at $579 in Q1 2026.
  • 354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Ankerstar Wealth's 13F filing for Q2 2026, filed 13 Aug 2026.